aTyr Pharma Stock Price, News & Analysis (NASDAQ:LIFE)

$3.90 -0.10 (-2.50 %)
(As of 12/12/2017 12:55 PM ET)
Previous Close$4.00
Today's Range$3.85 - $4.05
52-Week Range$2.10 - $6.50
Volume40,600 shs
Average Volume101,342 shs
Market Capitalization$118.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma logoaTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Receive LIFE News and Ratings via Email

Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryLife Sciences Tools & Services
SectorHealthcare
SymbolNASDAQ:LIFE
CUSIP53217V10
Phone+1-858-7318389

Debt

Debt-to-Equity Ratio0.17%
Current Ratio9.49%
Quick Ratio9.49%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.65 per share
Price / Book1.47

Profitability

Trailing EPS($2.04)
Net Income$-57,850,000.00
Net MarginsN/A
Return on Equity-87.33%
Return on Assets-65.25%

Miscellaneous

Employees58
Outstanding Shares29,760,000

aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) posted its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.50) by $0.07. View aTyr Pharma's Earnings History.

Where is aTyr Pharma's stock going? Where will aTyr Pharma's stock price be in 2017?

4 brokers have issued 1-year price targets for aTyr Pharma's stock. Their predictions range from $2.85 to $7.00. On average, they anticipate aTyr Pharma's share price to reach $4.46 in the next year. View Analyst Ratings for aTyr Pharma.

Who are some of aTyr Pharma's key competitors?

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the folowing people:

  • John K. Clarke, Independent Chairman of the Board (Age 63)
  • Sanjay S. Shukla M.D., President, Chief Executive Officer, Chief Medical Officer (Age 45)
  • John T. Blake, Senior Vice President - Finance (Age 40)
  • David John King Ph.D., Senior Vice President - Research (Age 58)
  • Grove Matsuoka, Senior Vice President, Product Programs and Planning (Age 58)
  • Ashraf Amanullah Ph.D., Vice President, Biologics Development and Manufacturing (Age 49)
  • Sanuj K. Ravindran M.D., Chief Business Officer (Age 45)
  • Timothy P. Coughlin CPA, Director (Age 50)
  • Jeffrey S. Hatfield, Director
  • John D. Mendlein Ph.D., Director (Age 57)

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

Who owns aTyr Pharma stock?

aTyr Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Alyeska Investment Group L.P. (3.16%), Artal Group S.A. (1.05%), Victory Capital Management Inc. (0.38%) and Dimensional Fund Advisors LP (0.35%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.

Who sold aTyr Pharma stock? Who is selling aTyr Pharma stock?

aTyr Pharma's stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P.. View Insider Buying and Selling for aTyr Pharma.

Who bought aTyr Pharma stock? Who is buying aTyr Pharma stock?

aTyr Pharma's stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., Victory Capital Management Inc. and Dimensional Fund Advisors LP. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.

How do I buy aTyr Pharma stock?

Shares of aTyr Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is aTyr Pharma's stock price today?

One share of aTyr Pharma stock can currently be purchased for approximately $3.90.

How big of a company is aTyr Pharma?

aTyr Pharma has a market capitalization of $118.80 million. The biotechnology company earns $-57,850,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. aTyr Pharma employs 58 workers across the globe.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 John Hopkins Ct Ste 250, SAN DIEGO, CA 92121-1115, United States. The biotechnology company can be reached via phone at +1-858-7318389 or via email at [email protected]


MarketBeat Community Rating for aTyr Pharma (LIFE)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  492
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

aTyr Pharma (NASDAQ:LIFE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.252.252.202.00
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.46$4.46$4.46$3.62
Price Target Upside: 59.38% upside59.38% upside59.38% upside1.88% upside

aTyr Pharma (NASDAQ:LIFE) Consensus Price Target History

Price Target History for aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma (NASDAQ:LIFE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/7/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$7.00HighView Rating Details
8/15/2017BMO Capital MarketsSet Price TargetHold$4.00HighView Rating Details
3/20/2017CitigroupBoost Price TargetNeutral$3.00 -> $4.00MediumView Rating Details
3/18/2017J P Morgan Chase & CoReiterated RatingHoldMediumView Rating Details
3/31/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

aTyr Pharma (NASDAQ:LIFE) Earnings History and Estimates Chart

Earnings by Quarter for aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma (NASDAQ LIFE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.50)($0.43)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.57)($0.51)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.50)($0.56)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.67)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.71)($0.65)ViewN/AView Earnings Details
5/11/2016Q1($0.70)($0.68)ViewN/AView Earnings Details
3/30/2016Q4($0.52)($0.70)ViewN/AView Earnings Details
11/10/2015Q3($0.48)($0.48)ViewN/AView Earnings Details
8/12/2015Q215($0.53)($0.74)ViewN/AView Earnings Details
6/18/2015Q115($0.41)($0.38)ViewN/AView Earnings Details
11/5/2013Q313$0.97$1.02$926.10 million$936.00 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.96$0.72$952.06 million$944.00 millionViewN/AView Earnings Details
5/2/2013Q1 2013$1.04$1.07$958.56 million$963.00 millionViewN/AView Earnings Details
2/4/2013Q4 2012$1.11$1.11$988.85 million$998.90 millionViewN/AView Earnings Details
11/1/2012Q312$0.89$0.92$907.91 million$911.00 millionViewN/AView Earnings Details
7/31/2012$0.97$0.96ViewN/AView Earnings Details
2/7/2012$1.04$1.06ViewN/AView Earnings Details
10/25/2011$0.88$0.94ViewN/AView Earnings Details
7/28/2011$0.95$0.89ViewN/AView Earnings Details
4/26/2011$0.85$0.85ViewN/AView Earnings Details
2/3/2011$0.87$0.90ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

aTyr Pharma (NASDAQ:LIFE) Earnings Estimates

2017 EPS Consensus Estimate: ($2.00)
2018 EPS Consensus Estimate: ($2.32)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.49)($0.49)($0.49)
Q2 20171($0.50)($0.50)($0.50)
Q3 20171($0.53)($0.53)($0.53)
Q4 20171($0.48)($0.48)($0.48)
Q1 20181($0.53)($0.53)($0.53)
Q2 20181($0.56)($0.56)($0.56)
Q3 20181($0.60)($0.60)($0.60)
Q4 20181($0.63)($0.63)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for aTyr Pharma (NASDAQ:LIFE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

aTyr Pharma (NASDAQ LIFE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 58.32%
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma (NASDAQ LIFE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017John MendleinCEOBuy37,736$2.65$100,000.40View SEC Filing  
8/31/2017Paul SchimmelDirectorBuy94,336$2.65$249,990.40View SEC Filing  
4/24/2017John MendleinCEOBuy124$3.00$372.00View SEC Filing  
4/20/2017John MendleinCEOBuy2,552$3.00$7,656.00View SEC Filing  
12/21/2016Paul SchimmelDirectorBuy25,000$2.28$57,000.00View SEC Filing  
12/20/2016Ashraf AmanullahVPBuy11,000$2.25$24,750.00View SEC Filing  
12/19/2016John MendleinCEOBuy69,000$2.20$151,800.00View SEC Filing  
12/16/2016Paul SchimmelDirectorBuy50,000$2.48$124,000.00View SEC Filing  
5/11/2016Grove MatsuokaInsiderBuy12,412$3.04$37,732.48View SEC Filing  
4/14/2016Paul SchimmelDirectorBuy66,219$4.18$276,795.42View SEC Filing  
4/13/2016Paul SchimmelDirectorBuy9,835$3.85$37,864.75View SEC Filing  
4/12/2016Paul SchimmelDirectorBuy9,127$3.71$33,861.17View SEC Filing  
4/11/2016Paul SchimmelDirectorBuy32,659$3.57$116,592.63View SEC Filing  
4/8/2016Paul SchimmelDirectorBuy85,000$3.22$273,700.00View SEC Filing  
4/7/2016Paul SchimmelDirectorBuy40,000$3.19$127,600.00View SEC Filing  
4/6/2016Paul SchimmelDirectorBuy25,000$3.20$80,000.00View SEC Filing  
4/5/2016John MendleinCEOBuy2,500$3.55$8,875.00View SEC Filing  
4/5/2016Paul SchimmelDirectorBuy25,000$3.52$88,000.00View SEC Filing  
5/12/2015James E FlynnInsiderBuy50,000$14.00$700,000.00View SEC Filing  
5/12/2015Sofinnova Venture Partners Ix,Major ShareholderBuy320,000$14.00$4,480,000.00View SEC Filing  
5/29/2013David C UprichardDirectorSell2,010$74.04$148,820.40View SEC Filing  
5/28/2013John A CottinghamInsiderSell60,000$74.03$4,441,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

aTyr Pharma (NASDAQ LIFE) News Headlines

Source:
DateHeadline
aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare ConferenceaTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 7 at 9:24 AM
Zacks: Analysts Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.44 Earnings Per ShareZacks: Analysts Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.44 Earnings Per Share
www.americanbankingnews.com - December 4 at 3:14 PM
aTyr Pharma (LIFE) Cut to "Strong Sell" at ValuEngineaTyr Pharma (LIFE) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 8:34 AM
aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc ... - GlobeNewswire (press release)aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc ... - GlobeNewswire (press release)
globenewswire.com - November 28 at 10:00 AM
aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)
finance.yahoo.com - November 27 at 5:06 PM
aTyr Pharma, Inc. (LIFE) Given Average Recommendation of "Hold" by BrokeragesaTyr Pharma, Inc. (LIFE) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 21 at 8:16 AM
aTyr Pharma, Inc. (LIFE) Upgraded to "Buy" by Zacks Investment ResearchaTyr Pharma, Inc. (LIFE) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 18 at 6:40 AM
FY2017 EPS Estimates for aTyr Pharma, Inc. Raised by William Blair (LIFE)FY2017 EPS Estimates for aTyr Pharma, Inc. Raised by William Blair (LIFE)
www.americanbankingnews.com - November 17 at 8:52 PM
Atyr Pharma reports 3Q lossAtyr Pharma reports 3Q loss
finance.yahoo.com - November 17 at 1:16 PM
aTyr Pharma, Inc. (LIFE) Posts  Earnings Results, Beats Expectations By $0.07 EPSaTyr Pharma, Inc. (LIFE) Posts Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - November 15 at 12:43 PM
aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update - GlobeNewswire (press release)aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - November 15 at 4:14 AM
aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate UpdateaTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update
finance.yahoo.com - November 15 at 4:14 AM
aTyr Pharma, Inc. (LIFE) Set to Announce Quarterly Earnings on MondayaTyr Pharma, Inc. (LIFE) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 6:26 AM
aTyr Pharma Announces Leadership Transition - GlobeNewswire (press release)aTyr Pharma Announces Leadership Transition - GlobeNewswire (press release)
globenewswire.com - November 2 at 5:33 AM
aTyr Pharma Announces Leadership TransitionaTyr Pharma Announces Leadership Transition
finance.yahoo.com - November 2 at 5:33 AM
Head-To-Head Comparison: aTyr Pharma (LIFE) versus Its CompetitorsHead-To-Head Comparison: aTyr Pharma (LIFE) versus Its Competitors
www.americanbankingnews.com - October 28 at 3:30 PM
aTyr Pharma, Inc. (LIFE) Receives Average Recommendation of "Hold" from AnalystsaTyr Pharma, Inc. (LIFE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 27 at 7:58 AM
-$0.51 EPS Expected for aTyr Pharma, Inc. (LIFE) This Quarter-$0.51 EPS Expected for aTyr Pharma, Inc. (LIFE) This Quarter
www.americanbankingnews.com - October 26 at 5:26 PM
aTyr Pharma, Inc. (LIFE) Expected to Post Earnings of -$0.51 Per ShareaTyr Pharma, Inc. (LIFE) Expected to Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - October 7 at 6:26 PM
How Should You Think About aTyr Pharma Inc’s (LIFE) Risks?How Should You Think About aTyr Pharma Inc’s (LIFE) Risks?
finance.yahoo.com - October 5 at 8:18 AM
aTyr Pharma, Inc. (LIFE) Receives Consensus Rating of "Hold" from AnalystsaTyr Pharma, Inc. (LIFE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 2 at 4:32 AM
aTyr Pharma (LIFE) to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset ... - StreetInsider.comaTyr Pharma (LIFE) to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset ... - StreetInsider.com
www.streetinsider.com - September 29 at 1:58 PM
aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle SocietyaTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society
finance.yahoo.com - September 27 at 10:14 AM
 Brokerages Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.53 EPS Brokerages Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.53 EPS
www.americanbankingnews.com - September 19 at 12:26 AM
Piper Jaffray Companies Begins Coverage on aTyr Pharma, Inc. (LIFE)Piper Jaffray Companies Begins Coverage on aTyr Pharma, Inc. (LIFE)
www.americanbankingnews.com - September 10 at 10:14 AM
aTyr Pharma to Present at Two Upcoming Investor Conferences in SeptemberaTyr Pharma to Present at Two Upcoming Investor Conferences in September
finance.yahoo.com - September 6 at 2:03 AM
Insider Buying: aTyr Pharma, Inc. (LIFE) CEO Buys 37,736 Shares of StockInsider Buying: aTyr Pharma, Inc. (LIFE) CEO Buys 37,736 Shares of Stock
www.americanbankingnews.com - September 5 at 10:27 PM
Insider Buying: aTyr Pharma, Inc. (LIFE) Director Buys 94,336 Shares of StockInsider Buying: aTyr Pharma, Inc. (LIFE) Director Buys 94,336 Shares of Stock
www.americanbankingnews.com - September 5 at 10:26 PM
aTyr Pharma (LIFE) Reports $45M Private PlacementaTyr Pharma (LIFE) Reports $45M Private Placement
www.streetinsider.com - August 29 at 1:07 AM
aTyr Pharma Announces $45 Million Equity FinancingaTyr Pharma Announces $45 Million Equity Financing
finance.yahoo.com - August 28 at 8:05 PM
[$$] Publicly Traded Rare Disease Drug-Maker aTyr Pharma Gets $46 Million Lift[$$] Publicly Traded Rare Disease Drug-Maker aTyr Pharma Gets $46 Million Lift
finance.yahoo.com - August 28 at 8:05 PM
William Blair Analysts Lift Earnings Estimates for aTyr Pharma, Inc. (LIFE)William Blair Analysts Lift Earnings Estimates for aTyr Pharma, Inc. (LIFE)
www.americanbankingnews.com - August 17 at 8:22 AM
aTyr Pharma, Inc. (LIFE) Releases  Earnings Results, Beats Estimates By $0.06 EPSaTyr Pharma, Inc. (LIFE) Releases Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - August 15 at 2:38 PM
aTyr Pharma, Inc. (LIFE) Given "Hold" Rating at BMO Capital MarketsaTyr Pharma, Inc. (LIFE) Given "Hold" Rating at BMO Capital Markets
www.americanbankingnews.com - August 15 at 1:06 PM
aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology PipelineaTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
finance.yahoo.com - August 15 at 1:02 AM
Atyr Pharma reports 2Q lossAtyr Pharma reports 2Q loss
finance.yahoo.com - August 15 at 1:02 AM
aTyr Pharma, Inc. (NASDAQ:LIFE) Expected to Announce Earnings of -$0.57 Per ShareaTyr Pharma, Inc. (NASDAQ:LIFE) Expected to Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - August 13 at 2:24 AM
aTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial ResultsaTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results
finance.yahoo.com - August 11 at 6:08 AM
aTyr Pharma, Inc. (NASDAQ:LIFE) to Release Quarterly Earnings on TuesdayaTyr Pharma, Inc. (NASDAQ:LIFE) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
UPDATE 1-Contract medical research firm INC to buy inVentiv in $4.6 bln dealUPDATE 1-Contract medical research firm INC to buy inVentiv in $4.6 bln deal
www.businessinsider.com - May 11 at 11:47 PM
Contract medical research firm INC to buy inVentiv in $4.6 billion dealContract medical research firm INC to buy inVentiv in $4.6 billion deal
www.cnbc.com - May 11 at 11:47 PM
aTyr Pharma (LIFE) Reports Top-Line Results from Resolaris Phase 1b/2 TrialaTyr Pharma (LIFE) Reports Top-Line Results from Resolaris Phase 1b/2 Trial
www.streetinsider.com - April 24 at 7:23 PM
ATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal OfficersATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - April 4 at 8:02 AM
aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating ResultsaTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results
www.bizjournals.com - March 16 at 7:04 PM
ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 16 at 7:04 PM
aTyr Pharma (LIFE) Gains on Orphan Drug DesignationaTyr Pharma (LIFE) Gains on Orphan Drug Designation
www.baystreet.ca - March 3 at 11:14 PM
aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
us.rd.yahoo.com - March 3 at 6:13 PM
8:01 am aTyr Pharma announces that the European Medicines Agency has granted orphan drug designation to Resolaris for the treatment of limb girdle muscular dystrophy patients8:01 am aTyr Pharma announces that the European Medicines Agency has granted orphan drug designation to Resolaris for the treatment of limb girdle muscular dystrophy patients
us.rd.yahoo.com - March 3 at 6:13 PM
BUZZ-US STOCKS ON THE MOVE-Target, Frontier, aTyr Pharma, Intelsat - NasdaqBUZZ-US STOCKS ON THE MOVE-Target, Frontier, aTyr Pharma, Intelsat - Nasdaq
www.nasdaq.com - March 2 at 10:18 AM
aTyr Pharma (LIFE) Receives FDA Orphan Drug Designation for Treatment of LGMD with Resolaris - StreetInsider.comaTyr Pharma (LIFE) Receives FDA Orphan Drug Designation for Treatment of LGMD with Resolaris - StreetInsider.com
www.streetinsider.com - March 2 at 10:18 AM

SEC Filings

aTyr Pharma (NASDAQ:LIFE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

aTyr Pharma (NASDAQ:LIFE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

aTyr Pharma (NASDAQ LIFE) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.